Table 1.

Descriptive summary of reviewed studies on HIV disease progression among illicit drug users

	AIDS	Mortality	CD4	PVL	All
All	16 (100%) [32, 35, 36, 39, 49, 57, 58, 62, 63, 67, 69–71, 73–75]	23 (100%) [20, 24, 26, 27, 34, 37, 39, 42, 48, 52, 53, 57–59, 62–64, 67, 68, 70–73]	16 (100%) [23, 25, 26, 30, 33, 38, 43, 45, 47, 51, 61, 62, 65, 67, 69, 77]	15 (100%) [21, 28, 29, 31, 40, 41, 44, 47, 50, 54–56, 60, 66, 76]	58 (100%) [20–77]
Setting
North America	6 (38%) [32, 36, 39, 73–75]	9 (39%) [24, 27, 34, 39, 42, 53, 68, 72, 73]	6 (38%) [23, 30, 33, 45, 47, 77]	9 (60%) [21, 31, 40, 41, 44, 47, 54–56]	27 (47%) [21, 23, 24, 27, 30–34, 36, 39–42, 44, 45, 47, 53–56, 68, 72–75, 77]
Western Europe	4 (25%) [35, 49, 62, 67]	10 (43%) [20, 22, 26, 37, 48, 52, 59, 62, 63, 67]	6 (38%) [25, 26, 38, 61, 62, 67]	6 (40%) [28, 29, 50, 60, 66, 76]	21 (36%) [20, 22, 25, 26, 28, 29, 35, 37, 38, 48–50, 52, 59–62, 64, 66, 67, 76]
Asia	0 (0%)	0 (0%)	1 (6%) [51]	0 (0%)	1 (2%) [51]
Multi-centre	6 (38%) [57, 58, 63, 69–71]	5 (22%) [57, 58, 63, 70, 71]	2 (13%) [43, 69]	0 (0%)	7 (12%) [43, 57, 58, 63, 69–71]
Sample
Community	4 (25%) [32, 36, 39, 73]	7 (30%) [24, 34, 39, 53, 68, 72, 73]	6 (38%) [23, 30, 43, 45, 47, 77]	7 (47%) [31, 40, 41, 44, 47, 55, 56]	21 (36%) [23, 24, 30–32, 34, 36, 39–41, 43–45, 47, 53, 55, 56, 68, 72, 73, 77]
Clinical/Treatment	4 (25%) [49, 67, 74, 75]	10 (43%) [20, 22, 26, 27, 37, 42, 48, 59, 64, 67]	7 (44%) [25, 26, 33, 38, 51, 61, 67]	7 (47%) [21, 28, 29, 50, 60, 66, 76]	25 (43%) [20–22, 25–29, 33, 37, 38, 42, 48–51, 59–61, 64, 66, 67, 74–76]
Other	8 (50%) [35, 57, 58, 62, 63, 69–71]	7 (30%) [52, 57, 58, 62, 63, 70, 71]	2 (13%) [62, 69]	1 (7%) [54]	10 (17%) [35, 52, 54, 57, 58, 62, 63, 69–71]
Sample size, median (IQR)	600 (504 – 761)	487 (126 – 686)	238 (128 – 259)	189 (106 – 246)	363 (125 – 524)
Follow-up months, median (IQR)	61 (48 – 84)	56 (41 – 81)	45 (30 – 57)	12 (12 – 24)	44 (30 – 61)